Politician trade (Senate)

Dexcom (DXCM)Sen. Tina Smith disclosed a partial sale $100K–$250K

Sen. Tina Smith disclosed a partial sale of Dexcom in the $100K–$250K range.

$100,001–$250,000
Reported range · official band, not an exact amount
11 days
Disclosure lag
Traded
Apr 29, 2026
Disclosed
May 10, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 27, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“As previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R. Sayer notified the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) of his intent to retire from his role as Chief Executive Officer effective January 1, 2026.”
  2. Mar 16, 2026InsiderOfficer sold ~$110K of DXCM shares in the open market
  3. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  4. Apr 14, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM watchOS App Model/Catalog Number: SW13355 Software Version: Versions 2.9…
  5. Apr 14, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM iOS App Model/Catalog Number: SW12300 Software Version: Versions 2.9.0 t…
  6. Apr 14, 2026FDARecall: Brand Name: Dexcom ONE+ Continuous Glucose Monitoring System Product Name: Dexcom ONE+ iOS CGM App Model/Catalog Number: SW14244 Software Version: versions 1.5…
  7. Apr 15, 2026InsiderOfficer sold ~$107K of DXCM shares in the open market
  8. Apr 29, 2026 · this disclosureCongressDisclosed partial sale of DXCM — reported range $100,001 - $250,000

What came next

  1. Apr 29, 20265% stakeVanguard Portfolio Management reported a passive stake (13G) of 5.0%
  2. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  3. Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
  4. May 7, 2026CongressDisclosed sale of DXCM — reported range $100,001 - $250,000
  5. May 12, 2026InsiderDirector sold ~$61K of DXCM shares in the open market
  6. May 15, 2026InsiderOfficer sold ~$102K of DXCM shares in the open market
  7. May 21, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
  8. May 21, 2026InsiderChair sold ~$1.93M of DXCM shares in the open market
  9. May 27, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 US Retail Sensor/Transmitter 1-pack Model/Catalog Number: STP-AT-012 Softwar…
  10. Jun 3, 2026InsiderOfficer sold ~$359K of DXCM shares in the open market
  11. Jun 4, 2026InsiderOfficer sold ~$364K of DXCM shares in the open market
  12. Jun 8, 2026FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System
  13. Jun 12, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
  14. Jun 15, 2026Insider · 2 peopleInsiders: 3 sales (~$425K)
  15. Jul 6, 2026InsiderChair sold ~$1.93M of DXCM shares in the open market
  16. Jul 15, 2026InsiderOfficer sold ~$127K of DXCM shares in the open market
  17. Jul 20, 2026InsiderChair sold ~$2.04M of DXCM shares in the open market
  18. Jul 30, 2026Company filing · Form 8-K · ResultsReported its results
  19. Jul 31, 2026InsiderDirector sold ~$160K of DXCM shares in the open market
  20. Aug 3, 2026InsiderDirector sold ~$171K of DXCM shares in the open market
View the official recordSenate eFD periodic transaction report

How to read Senate eFD periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Dexcom

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 16 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.

Other recent filings by Sen. Tina Smith

The full history of Sen. Tina Smith is on the profile page.

How this filing works

Other disclosures at Dexcom

Everything OQRO holds on this company is on its DXCM page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data